MedPath

Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

Generic Name
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
3ME9TTI5QB
Background

Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

These AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte. This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.

Associated Conditions
-
Associated Therapies
-
openpr.com
·

Traumatic Brain Injury Treatment Market 2034: EMA, PDMA

The Traumatic Brain Injury (TBI) market is expected to grow significantly by 2034, driven by new therapies and increasing prevalence. Key companies include VeriNOS Pharmaceuticals GmbH and Cellvation, Inc., with treatments like Ronopterin and CEVA101. The US, EU4, UK, and Japan show varying market sizes and incident cases, with males more affected. Advances in treatment and diagnosis are improving outcomes.
finance.yahoo.com
·

Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem

Hope Biosciences Research Foundation (HBRF) received FDA Authorization to administer HB-adMSCs to pediatric JIA patients aged 2-16, marking the first FDA authorization for this cell type in JIA and HBRF's first pediatric clinical trial. The Phase II trial (NCT06623240) will enroll 66 participants for 72 weeks, with a randomized, double-blind, crossover design. HBRF aims to improve quality of life for JIA patients and create hope for the wider JIA community.
openpr.com
·

Traumatic Brain Injury Clinical Trials 2024: EMA, PDMA, FDA

Global efforts in Traumatic Brain Injury (TBI) treatment development are advancing, with companies like SHINKEI Therapeutics and SanBio leading in innovative therapies. The 2024 DelveInsight report highlights ongoing clinical trials, emerging drugs, and market dynamics, emphasizing the importance of early intervention and the potential impact of new treatments on TBI management.
morningstar.com
·

Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy in MS

Hope Biosciences Research Foundation reports positive Phase II trial results for stem cell therapy in MS, showing significant improvements in physical and mental health.
finance.yahoo.com
·

Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem

Hope Biosciences Research Foundation (HBRF) reports positive Phase II trial results for its adipose-derived autologous mesenchymal stem cell therapy (HB-adMSCs) in treating mild to moderate relapsing remitting multiple sclerosis (MS), showing significant improvements in physical and mental health compared to placebo.
© Copyright 2025. All Rights Reserved by MedPath